BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Self WH, Wunderink RG, Williams DJ, Zhu Y, Anderson EJ, Balk RA, Fakhran SS, Chappell JD, Casimir G, Courtney DM, Trabue C, Waterer GW, Bramley A, Magill S, Jain S, Edwards KM, Grijalva CG. Staphylococcus aureus Community-acquired Pneumonia: Prevalence, Clinical Characteristics, and Outcomes. Clin Infect Dis 2016;63:300-9. [PMID: 27161775 DOI: 10.1093/cid/ciw300] [Cited by in Crossref: 66] [Cited by in F6Publishing: 51] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Talagtag M, Patel TS, Scappaticci GB, Perissinotti AJ, Schepers AJ, Petty LA, Pettit KM, Burke PW, Bixby DL, Marini BL. Utility of methicillin-resistant Staphylococcus aureus (MRSA) nasal screening in patients with acute myeloid leukemia (AML). Transpl Infect Dis 2021;:e13612. [PMID: 33825279 DOI: 10.1111/tid.13612] [Reference Citation Analysis]
2 Carvalhaes CG, Sader HS, Rhomberg PR, Mendes RE. Tedizolid activity against a multicentre worldwide collection of Staphylococcus aureus and Streptococcus pneumoniae recovered from patients with pneumonia (2017-2019). Int J Infect Dis 2021;107:92-100. [PMID: 33857605 DOI: 10.1016/j.ijid.2021.04.014] [Reference Citation Analysis]
3 Nik Zuraina NMN, Goni MD, Amalina KN, Hasan H, Mohamad S, Suraiya S. Thermostable Heptaplex PCR Assay for the Detection of Six Respiratory Bacterial Pathogens. Diagnostics (Basel) 2021;11:753. [PMID: 33922299 DOI: 10.3390/diagnostics11050753] [Reference Citation Analysis]
4 Dunaway S, Orwig KW, Arbogast ZQ, Myers ZL, Sizemore JA, Giancola SE. Evaluation of a pharmacy-driven methicillin-resistant Staphylococcus aureus surveillance protocol in pneumonia. Int J Clin Pharm 2018;40:526-32. [DOI: 10.1007/s11096-018-0647-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
5 Fernández L, Cima-Cabal MD, Duarte AC, Rodríguez A, García-Suárez MDM, García P. Gram-Positive Pneumonia: Possibilities Offered by Phage Therapy. Antibiotics (Basel) 2021;10:1000. [PMID: 34439050 DOI: 10.3390/antibiotics10081000] [Reference Citation Analysis]
6 Lat I, Daley MJ, Shewale A, Pangrazzi MH, Hammond D, Olsen KM; DEFINE study group and the Discovery Research Network. A Multicenter, Prospective, Observational Study to Determine Predictive Factors for Multidrug-Resistant Pneumonia in Critically Ill Adults: The DEFINE Study. Pharmacotherapy 2019;39:253-60. [PMID: 30101412 DOI: 10.1002/phar.2171] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
7 Zheng DJ, Abou Taka M, Heit B. Role of Apoptotic Cell Clearance in Pneumonia and Inflammatory Lung Disease. Pathogens 2021;10:134. [PMID: 33572846 DOI: 10.3390/pathogens10020134] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
8 Burnham JP, Kakol MK, Vazquez Guillamet MC. Methicillin-resistant Staphylococcus aureus Nasal Screening Adds Limited Value to the Choice of Empiric Antibiotics in Community-acquired Pneumonia. Clin Infect Dis 2019;68:1251. [PMID: 30304410 DOI: 10.1093/cid/ciy868] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Cilloniz C, Dominedò C, Gabarrús A, Garcia-Vidal C, Becerril J, Tovar D, Moreno E, Pericás JM, Vargas CR, Torres A. Methicillin-susceptible staphylococcus aureus in community-acquired pneumonia: Risk factors and outcomes. J Infect 2021;82:76-83. [PMID: 33144192 DOI: 10.1016/j.jinf.2020.10.032] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Parente DM, Cunha CB, Mylonakis E, Timbrook TT. The Clinical Utility of Methicillin-Resistant Staphylococcus aureus (MRSA) Nasal Screening to Rule Out MRSA Pneumonia: A Diagnostic Meta-analysis With Antimicrobial Stewardship Implications. Clin Infect Dis 2018;67:1-7. [PMID: 29340593 DOI: 10.1093/cid/ciy024] [Cited by in Crossref: 61] [Cited by in F6Publishing: 48] [Article Influence: 20.3] [Reference Citation Analysis]
11 David MZ. MRSA community pneumonia: a global perspective on resistance. The Lancet Infectious Diseases 2016;16:1309-10. [DOI: 10.1016/s1473-3099(16)30312-7] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
12 Waters CD, Caraccio J. Rate of positive cultures necessitating definitive treatment in patients receiving empiric vancomycin therapy. Infect Control Hosp Epidemiol 2018;39:989-90. [PMID: 29893660 DOI: 10.1017/ice.2018.123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Xia H, Gao J, Xiu M, Li D. Community-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus in a Chinese adult: A case report. Medicine (Baltimore) 2020;99:e20914. [PMID: 32590802 DOI: 10.1097/MD.0000000000020914] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Chalmers JD, Reyes LF, Aliberti S, Restrepo MI. Empirical Coverage of Methicillin-Resistant Staphylococcus aureus in Community-Acquired Pneumonia: Those Who Do Not Remember the Past Are Doomed to Repeat It. Clin Infect Dis 2016;63:1145-6. [PMID: 27402822 DOI: 10.1093/cid/ciw464] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
15 Liapikou A, Cilloniz C, Palomeque A, Torres T. Emerging antibiotics for community-acquired pneumonia. Expert Opin Emerg Drugs 2019;24:221-31. [PMID: 31657962 DOI: 10.1080/14728214.2019.1685494] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
16 Mergenhagen KA, Starr KE, Wattengel BA, Lesse AJ, Sumon Z, Sellick JA. Determining the Utility of Methicillin-Resistant Staphylococcus aureus Nares Screening in Antimicrobial Stewardship. Clin Infect Dis 2020;71:1142-8. [PMID: 31573026 DOI: 10.1093/cid/ciz974] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
17 Patil SM, Beck PP, Patel TP, Dale Swaney R, Dandachi D, Krvavac A. Electronic Vaping-Induced Methicillin-Sensitive Staphylococcus Aureus Pneumonia and Empyema. Case Rep Infect Dis 2021;2021:6651430. [PMID: 33747579 DOI: 10.1155/2021/6651430] [Reference Citation Analysis]
18 de Miguel-díez J, López-de-andrés A, Hernández-barrera V, Jiménez-trujillo I, Méndez-bailón M, de Miguel-yanes JM, Jiménez-garcía R. Impact of COPD on outcomes in hospitalized patients with community-acquired pneumonia: Analysis of the Spanish national hospital discharge database (2004–2013). European Journal of Internal Medicine 2017;43:69-76. [DOI: 10.1016/j.ejim.2017.06.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
19 Roger C, Roberts JA, Muller L. Clinical Pharmacokinetics and Pharmacodynamics of Oxazolidinones. Clin Pharmacokinet 2018;57:559-75. [PMID: 29063519 DOI: 10.1007/s40262-017-0601-x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 27] [Article Influence: 13.3] [Reference Citation Analysis]
20 Gil R, Webb BJ. Strategies for prediction of drug-resistant pathogens and empiric antibiotic selection in community-acquired pneumonia. Curr Opin Pulm Med 2020;26:249-59. [PMID: 32101906 DOI: 10.1097/MCP.0000000000000670] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Wicha WW, Strickmann DB, Paukner S. Pharmacokinetics/pharmacodynamics of lefamulin in a neutropenic murine pneumonia model with Staphylococcus aureus and Streptococcus pneumoniae. J Antimicrob Chemother 2019;74:iii11-8. [PMID: 30949707 DOI: 10.1093/jac/dkz086] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 9.5] [Reference Citation Analysis]
22 Liu CW, Lin SP, Wang WY, Huang YH. Influenza With Community-Associated Methicillin-Resistant Staphylococcus Aureus Pneumonia. Am J Med Sci 2019;358:289-93. [PMID: 31543102 DOI: 10.1016/j.amjms.2019.07.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
23 Block H, Zarbock A. A Fragile Balance: Does Neutrophil Extracellular Trap Formation Drive Pulmonary Disease Progression? Cells 2021;10:1932. [PMID: 34440701 DOI: 10.3390/cells10081932] [Reference Citation Analysis]
24 Teng F, Wan TT, Guo SB, Liu X, Cai JF, Qi X, Liu WX. Outcome prediction using the Mortality in Emergency Department Sepsis score combined with procalcitonin for influenza patients. Med Clin (Barc) 2019;153:411-7. [PMID: 31174861 DOI: 10.1016/j.medcli.2019.03.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
25 Yamada KJ, Heim CE, Aldrich AL, Gries CM, Staudacher AG, Kielian T. Arginase-1 Expression in Myeloid Cells Regulates Staphylococcus aureus Planktonic but Not Biofilm Infection. Infect Immun 2018;86:e00206-18. [PMID: 29661929 DOI: 10.1128/IAI.00206-18] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
26 Finch S, Keir HR, Dicker AJ, Chalmers JD. The past decade in bench research into pulmonary infectious diseases: What do clinicians need to know? Respirology 2017;22:1062-72. [PMID: 28657170 DOI: 10.1111/resp.13106] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
27 Parente DM, Cunha CB, Mylonakis E, Timbrook TT. Reply to Burnham, Kakol, and Vazquez-Guillamet. Clin Infect Dis 2019;68:1251-2. [PMID: 30304399 DOI: 10.1093/cid/ciy869] [Reference Citation Analysis]
28 Del Rosal T, Caminoa MB, González-Guerrero A, Falces-Romero I, Romero-Gómez MP, Baquero-Artigao F, Sainz T, Méndez-Echevarría A, Escosa-García L, Aracil FJ, Calvo C. Outcome of Severe Bacterial Pneumonia in the Era of Pneumococcal Vaccination. Front Pediatr 2020;8:576519. [PMID: 33384973 DOI: 10.3389/fped.2020.576519] [Reference Citation Analysis]
29 Self WH, Wunderink RG, Williams DJ, Waterer GW, Jain S, Edwards KM, Grijalva CG. Reply to Chalmers et al. Clin Infect Dis 2016;63:1146-7. [PMID: 27402823 DOI: 10.1093/cid/ciw466] [Reference Citation Analysis]
30 Jones BE, Brown KA, Jones MM, Huttner BD, Greene T, Sauer BC, Madaras-Kelly K, Rubin MA, Bidwell Goetz M, Samore MH. Variation in Empiric Coverage Versus Detection of Methicillin-Resistant Staphylococcus aureus and Pseudomonas aeruginosa in Hospitalizations for Community-Onset Pneumonia Across 128 US Veterans Affairs Medical Centers. Infect Control Hosp Epidemiol 2017;38:937-44. [PMID: 28633678 DOI: 10.1017/ice.2017.98] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
31 Teng F, Liu X, Guo SB, Li Z, Ji WQ, Zhang F, Zhu XM. Community-acquired bacterial co-infection predicts severity and mortality in influenza-associated pneumonia admitted patients. J Infect Chemother 2019;25:129-36. [PMID: 30448361 DOI: 10.1016/j.jiac.2018.10.014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
32 Baby N, Faust AC, Smith T, Sheperd LA, Knoll L, Goodman EL. Nasal Methicillin-Resistant Staphylococcus aureus (MRSA) PCR Testing Reduces the Duration of MRSA-Targeted Therapy in Patients with Suspected MRSA Pneumonia. Antimicrob Agents Chemother 2017;61:e02432-16. [PMID: 28137813 DOI: 10.1128/AAC.02432-16] [Cited by in Crossref: 31] [Cited by in F6Publishing: 8] [Article Influence: 6.2] [Reference Citation Analysis]
33 Corrêa RA, Costa AN, Lundgren F, Michelin L, Figueiredo MR, Holanda M, Gomes M, Teixeira PJZ, Martins R, Silva R, Athanazio RA, Silva RMD, Pereira MC. 2018 recommendations for the management of community acquired pneumonia. J Bras Pneumol 2018;44:405-23. [PMID: 30517341 DOI: 10.1590/S1806-37562018000000130] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
34 Chaudhry B, Alekseyev K, Didenko L, Malek A, Ryklin G. Post COVID-19 MSSA pneumonia. SAGE Open Med Case Rep 2021;9:2050313X211005996. [PMID: 33889412 DOI: 10.1177/2050313X211005996] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Welte T, Kantecki M, Stone GG, Hammond J. Ceftaroline fosamil as a potential treatment option for Staphylococcus aureus community-acquired pneumonia in adults. International Journal of Antimicrobial Agents 2019;54:410-22. [DOI: 10.1016/j.ijantimicag.2019.08.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
36 Webb BJ, Sorensen J, Mecham I, Buckel W, Ooi L, Jephson A, Dean NC. Antibiotic Use and Outcomes After Implementation of the Drug Resistance in Pneumonia Score in ED Patients With Community-Onset Pneumonia. Chest 2019;156:843-51. [PMID: 31077649 DOI: 10.1016/j.chest.2019.04.093] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
37 Brann KR, Fullerton MS, Onyilagha FI, Prince AA, Kurten RC, Rom JS, Blevins JS, Smeltzer MS, Voth DE. Infection of Primary Human Alveolar Macrophages Alters Staphylococcus aureus Toxin Production and Activity. Infect Immun 2019;87:e00167-19. [PMID: 31010814 DOI: 10.1128/IAI.00167-19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
38 Bassetti M, Labate L, Melchio M, Robba C, Battaglini D, Ball L, Pelosi P, Giacobbe DR. Current pharmacotherapy for methicillin-resistant Staphylococcus aureus (MRSA) pneumonia. Expert Opin Pharmacother 2021;:1-14. [PMID: 34882041 DOI: 10.1080/14656566.2021.2010706] [Reference Citation Analysis]
39 McCurdy S, Keedy K, Lawrence L, Nenninger A, Sheets A, Quintas M, Cammarata S. Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial. Antimicrob Agents Chemother 2020;64:e01949-19. [PMID: 31844013 DOI: 10.1128/AAC.01949-19] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
40 Mergenhagen KA, Croix M, Starr KE, Sellick JA, Lesse AJ. Utility of Methicillin-Resistant Staphylococcus aureus Nares Screening for Patients with a Diabetic Foot Infection. Antimicrob Agents Chemother 2020;64:e02213-19. [PMID: 31988097 DOI: 10.1128/AAC.02213-19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
41 Ma J, Liu W, Wang B, Yu S, Yu L, Song B, Yu Y, Zhu Z, Cui Y. Als3-Th-cell-epitopes plus the novel combined adjuvants of CpG, MDP, and FIA synergistically enhanced the immune response of recombinant TRAP derived from Staphylococcus aureus in mice. Immun Inflamm Dis 2021;9:971-83. [PMID: 34010502 DOI: 10.1002/iid3.456] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
42 Giulieri SG, Tong SYC, Williamson DA. Using genomics to understand meticillin- and vancomycin-resistant Staphylococcus aureus infections. Microb Genom 2020;6. [PMID: 31913111 DOI: 10.1099/mgen.0.000324] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
43 Eshwara VK, Mukhopadhyay C, Rello J. Community-acquired bacterial pneumonia in adults: An update. Indian J Med Res 2020;151:287-302. [PMID: 32461392 DOI: 10.4103/ijmr.IJMR_1678_19] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
44 Lupia T, Corcione S, Mornese Pinna S, De Rosa FG. New cephalosporins for the treatment of pneumonia in internal medicine wards. J Thorac Dis 2020;12:3747-63. [PMID: 32802454 DOI: 10.21037/jtd-20-417] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
45 Anai S, Ibusuki R, Takao T, Okushima K, Sakurai Y, Hisasue J, Furukawa T, Shiraishi N, Takaki Y, Hara N. Splenic volume in pneumococcal pneumonia patients is associated with disease severity and mortality. J Infect Chemother 2020;26:977-85. [PMID: 32376162 DOI: 10.1016/j.jiac.2020.04.023] [Reference Citation Analysis]
46 Cvetanovska M, Milenovic Z, Grozdanovski K, Demiri I, Spasovska K, Cvetanovski V. The Impact of Pneumonia on the Course and Outcome in Patients with Seasonal Influzenza. Pril (Makedon Akad Nauk Umet Odd Med Nauki) 2020;41:63-70. [PMID: 33011704 DOI: 10.2478/prilozi-2020-0034] [Reference Citation Analysis]
47 van de Veerdonk FL, Gresnigt MS, Verweij PE, Netea MG. Personalized medicine in influenza: a bridge too far or the near future? Curr Opin Pulm Med 2017;23:237-40. [PMID: 28257314 DOI: 10.1097/MCP.0000000000000378] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
48 Mizusawa M, Carroll KC. Novel strategies for rapid identification and susceptibility testing of MRSA. Expert Rev Anti Infect Ther 2020;18:759-78. [PMID: 32329637 DOI: 10.1080/14787210.2020.1760842] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
49 Falcó V, Burgos J, Almirante B. Ceftobiprole medocaril for the treatment of community-acquired pneumonia. Expert Opin Pharmacother 2018;19:1503-9. [PMID: 30198789 DOI: 10.1080/14656566.2018.1516749] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
50 Mallidi MG, Slocum GW, Peksa GD, DeMott JM. Impact of Prior-to-Admission Methicillin-Resistant Staphylococcus aureus Nares Screening in Critically Ill Adults With Pneumonia. Ann Pharmacother 2022;56:124-30. [PMID: 34096323 DOI: 10.1177/10600280211023209] [Reference Citation Analysis]
51 Shindo Y, Hasegawa Y. Regional differences in antibiotic-resistant pathogens in patients with pneumonia: Implications for clinicians. Respirology 2017;22:1536-46. [PMID: 28779516 DOI: 10.1111/resp.13135] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
52 Strehlitz A, Goldmann O, Pils MC, Pessler F, Medina E. An Interferon Signature Discriminates Pneumococcal From Staphylococcal Pneumonia. Front Immunol 2018;9:1424. [PMID: 29988532 DOI: 10.3389/fimmu.2018.01424] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
53 Sellarès-Nadal J, Burgos J, Falcó V, Almirante B. Investigational and Experimental Drugs for Community-Acquired Pneumonia: the Current Evidence. J Exp Pharmacol 2020;12:529-38. [PMID: 33239925 DOI: 10.2147/JEP.S259286] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Serrano L, Ruiz LA, Martinez-Indart L, España PP, Gómez A, Uranga A, García M, Santos B, Artaraz A, Zalacain R. Non-bacteremic pneumococcal pneumonia: general characteristics and early predictive factors for poor outcome. Infect Dis (Lond) 2020;52:603-11. [PMID: 32552142 DOI: 10.1080/23744235.2020.1772991] [Reference Citation Analysis]
55 Howell CK, Paciullo CA, Lyon GM, Neujahr D, Lyu P, Cotsonis G, Hurtik M. Effect of positive perioperative donor and recipient respiratory bacterial cultures on early post-transplant outcomes in lung transplant recipients. Transpl Infect Dis 2017;19. [PMID: 28803455 DOI: 10.1111/tid.12760] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
56 Kamuren Z, Kigen G, Keter A, Maritim A. Characteristics of patients with thromboembolic disorders on warfarin therapy in resource limited settings. BMC Health Serv Res 2018;18:723. [PMID: 30231891 DOI: 10.1186/s12913-018-3537-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]